Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

FOPO nets $40.5mm for Five Prime

Executive Summary

Five Prime Therapeutics Inc. (therapies for cancer and inflammatory diseases) netted $40.5mm through the follow-on public offering of 3.45mm common shares (including the overallotment) at $12.50 each. Some of the funds will support ongoing clinical trials of its CSF1R antibody FPA008 for autoimmune disease, and to move preclinical FPA144, an FGFR2b antibody for gastric cancer, into the clinic.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies